MX2023010455A - Métodos y composiciones para tratar enfermedades. - Google Patents
Métodos y composiciones para tratar enfermedades.Info
- Publication number
- MX2023010455A MX2023010455A MX2023010455A MX2023010455A MX2023010455A MX 2023010455 A MX2023010455 A MX 2023010455A MX 2023010455 A MX2023010455 A MX 2023010455A MX 2023010455 A MX2023010455 A MX 2023010455A MX 2023010455 A MX2023010455 A MX 2023010455A
- Authority
- MX
- Mexico
- Prior art keywords
- disease
- protein
- compositions
- treatment
- methods
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- -1 abatacept Proteins 0.000 abstract 4
- 102000008203 CTLA-4 Antigen Human genes 0.000 abstract 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 abstract 2
- 229940045513 CTLA4 antagonist Drugs 0.000 abstract 2
- 108010002350 Interleukin-2 Proteins 0.000 abstract 2
- 102000000588 Interleukin-2 Human genes 0.000 abstract 2
- 229960003697 abatacept Drugs 0.000 abstract 2
- 108700025316 aldesleukin Proteins 0.000 abstract 2
- 229960005310 aldesleukin Drugs 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
- A61N1/36082—Cognitive or psychiatric applications, e.g. dementia or Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Child & Adolescent Psychology (AREA)
- Developmental Disabilities (AREA)
- Psychology (AREA)
- Radiology & Medical Imaging (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163159919P | 2021-03-11 | 2021-03-11 | |
| US202163225846P | 2021-07-26 | 2021-07-26 | |
| US202263310839P | 2022-02-16 | 2022-02-16 | |
| PCT/US2022/019748 WO2022192536A1 (en) | 2021-03-11 | 2022-03-10 | Methods and compositions for treatment of disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023010455A true MX2023010455A (es) | 2023-11-28 |
Family
ID=83228307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023010455A MX2023010455A (es) | 2021-03-11 | 2022-03-10 | Métodos y composiciones para tratar enfermedades. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240148827A1 (https=) |
| EP (1) | EP4304624A4 (https=) |
| JP (1) | JP2024509911A (https=) |
| KR (1) | KR20230169147A (https=) |
| AU (1) | AU2022235091A1 (https=) |
| CA (1) | CA3211627A1 (https=) |
| MX (1) | MX2023010455A (https=) |
| WO (1) | WO2022192536A1 (https=) |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040022787A1 (en) * | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
| EP1878440A1 (en) * | 2006-07-13 | 2008-01-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta cell activator compounds |
| WO2008127298A2 (en) * | 2006-10-24 | 2008-10-23 | Subroto Chatterjee | Staphylococcal enterotoxin b peptide compositions and methods of use |
| US9044459B2 (en) * | 2008-12-05 | 2015-06-02 | Als Therapy Development Institute | Method for the treatment of neurodegenerative diseases |
| EP2367849B1 (en) * | 2008-12-05 | 2017-11-01 | ALS Therapy Development Institute | Method for the treatment of neurodegenerative diseases |
| CN102573500A (zh) * | 2009-08-06 | 2012-07-11 | 纽拉尔图斯制药公司 | 巨噬细胞相关疾病的治疗 |
| PL3053932T3 (pl) * | 2010-02-19 | 2021-03-08 | Xencor, Inc. | Nowe immunoadhezyny CTLA4-IG |
| KR102220006B1 (ko) * | 2011-03-11 | 2021-02-24 | 아시스땅스 퍼블리끄-오삐또 드 빠리 | 자가면역 - 관련 또는 염증성 장애를 치료하기 위한 저용량 ｉｌ２ 의 용도 |
| EP2734232B1 (en) * | 2011-07-19 | 2017-11-01 | Philogen S.p.A. | Sequential anti-ctla4 and targeted il-2 therapy |
| WO2013041029A1 (en) * | 2011-09-23 | 2013-03-28 | Igenimed Pharmaceuticals Inc. | Novel soluble ctla4 variants |
| US20140044675A1 (en) * | 2012-08-10 | 2014-02-13 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
| WO2014206899A1 (en) * | 2013-06-25 | 2014-12-31 | Icm (Institut Du Cerveau Et De La Moelle Épinière) | Boosting treg cells for treating alzheimer disease and related disorders |
| US20170233485A1 (en) * | 2014-08-18 | 2017-08-17 | Biogen Ma Inc. | Anti-cd40 antibodies and uses thereof |
| EP3192805A1 (en) * | 2016-01-15 | 2017-07-19 | Humanitas Mirasole S.p.A. | Inhibitors of t cell activation or stimulation and uses thereof |
| JP7181862B2 (ja) * | 2016-10-18 | 2022-12-01 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | 腫瘍浸潤リンパ球および治療の方法 |
| US11077172B2 (en) * | 2016-11-08 | 2021-08-03 | Delinia, Inc. | IL-2 variants for the treatment of psoriasis |
| CA3103603A1 (en) * | 2018-06-13 | 2019-12-19 | Akron Biotechnology, LLC. | Method to prepare therapeutically active aldesleukin highly stable in liquid pharmaceutical compositions |
| JP2022510377A (ja) * | 2018-12-03 | 2022-01-26 | デルマタ・セラピューティクス，エルエルシー | 状態の処置のための組成物 |
| CN113795271A (zh) * | 2019-03-08 | 2021-12-14 | 森德治疗公司 | 与irgd共施用以治疗癌症的低剂量细胞因子 |
| CN109999179A (zh) * | 2019-05-08 | 2019-07-12 | 山东省分析测试中心 | 低剂量白介素2用于制备治疗阿尔茨海默病药物中的应用 |
-
2022
- 2022-03-10 WO PCT/US2022/019748 patent/WO2022192536A1/en not_active Ceased
- 2022-03-10 MX MX2023010455A patent/MX2023010455A/es unknown
- 2022-03-10 US US18/280,632 patent/US20240148827A1/en active Pending
- 2022-03-10 CA CA3211627A patent/CA3211627A1/en active Pending
- 2022-03-10 AU AU2022235091A patent/AU2022235091A1/en active Pending
- 2022-03-10 EP EP22767990.9A patent/EP4304624A4/en active Pending
- 2022-03-10 JP JP2023555206A patent/JP2024509911A/ja active Pending
- 2022-03-10 KR KR1020237034557A patent/KR20230169147A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4304624A1 (en) | 2024-01-17 |
| US20240148827A1 (en) | 2024-05-09 |
| EP4304624A4 (en) | 2025-02-19 |
| AU2022235091A9 (en) | 2023-10-12 |
| WO2022192536A1 (en) | 2022-09-15 |
| JP2024509911A (ja) | 2024-03-05 |
| KR20230169147A (ko) | 2023-12-15 |
| AU2022235091A1 (en) | 2023-09-21 |
| CA3211627A1 (en) | 2022-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2020252418A3 (en) | Novel interleukin-2 variants for the treatment of cancer | |
| PH12018502634A1 (en) | Topical compositions of apremilast | |
| NO20053077L (no) | Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer. | |
| MX2021015353A (es) | Composiciones y métodos para inmunoterapia de cáncer. | |
| MX2021004431A (es) | Procesos novedosos. | |
| MX2023003677A (es) | Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos. | |
| WO2022256500A3 (en) | Dll3 targeting trispecific proteins and methods of use | |
| PH12021551232A1 (en) | Haloallylamine compounds and application thereof | |
| CR20230177A (es) | Compuestos y composiciones como moduladores de señalización tlr | |
| WO2022256499A3 (en) | Bcma targeting trispecific proteins and methods of use | |
| EP4552693A3 (en) | Collagen peptide-based medicament compositions and devices and methods of production and use thereof | |
| EP4566629A3 (en) | Use of low volume plasma exchange for the treatment of alzheimer s disease in early and middle stages | |
| SA521420957B1 (ar) | FXIa تركيبة جديدة ثابتة عالية التركيز لأجسام مضادة تعمل ضد | |
| MX2025014320A (es) | Compuestos nitrogenados aromaticos, metodos de preparacion y usos medicinales | |
| WO2020198662A8 (en) | Clec9a-based chimeric protein complexes | |
| MX2023010661A (es) | Moléculas de union al receptor leucocitario humano similar a inmunoglobulina b1 (lilrb1) y al receptor leucocitario humano similar a inmunoglobulina b2 (lilrb2) y usos para las mismas. | |
| WO2019195714A8 (en) | Methods and compositions for treating skin disease with recombinant microorganisms | |
| EP4480492A3 (en) | Novel insulin analogues and uses thereof | |
| MX2022006052A (es) | Inhibidores de la caspasa 6 y usos de los mismos. | |
| WO2023043870A8 (en) | Chewing gum formulation of lsd and methods of use thereof | |
| JOP20250174A1 (ar) | بروتينات اندماج il-12 fc | |
| MX2023010455A (es) | Métodos y composiciones para tratar enfermedades. | |
| EP4588487A3 (en) | Treatment of warts | |
| WO2019160806A3 (en) | Novel crystalline forms of tamibarotene for treatment of cancer | |
| MX2023010545A (es) | Inhibidores de integrinas alfa v beta 6 y alfa v beta 1 y usos de los mismos. |